Last Updated : March 3, 2025
Details
FilesGeneric Name:
trifluridine and tipiracil
Project Status:
Complete
Therapeutic Area:
Metastatic colorectal cancer
Manufacturer:
Taiho Pharma Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Lonsurf
Project Line:
Reimbursement Review
Project Number:
PC0330-000
Call for patient/clinician input closed:
Tumour Type:
Gastrointestinal
NOC Status at Filing:
N/A
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
LONSURF, in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
LONSURF, in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | July 04, 2023 |
|---|---|
| Call for patient/clinician input closed | August 25, 2023 |
| Clarification: - Patient input submission received from Colorectal Cancer Canada, and Colorectal Cancer Resource & Action Network (CCRAN) | |
| Submission received | August 15, 2023 |
| Submission accepted | August 29, 2023 |
| Review initiated | August 30, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | November 16, 2023 |
| Deadline for sponsors comments | November 27, 2023 |
| CADTH review report(s) and responses to comments provided to sponsor | December 21, 2023 |
| Expert committee meeting (initial) | January 10, 2024 |
| Draft recommendation issued to sponsor | January 23, 2024 |
| Draft recommendation posted for stakeholder feedback | February 01, 2024 |
| End of feedback period | February 15, 2024 |
| Final recommendation issued to sponsor and drug plans | February 29, 2024 |
| Final recommendation posted | March 19, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | March 14, 2024 |
| CADTH review report(s) posted | June 14, 2024 |
Files
Last Updated : March 3, 2025